WebJan 12, 2011 · San Francisco, CA - January 12, 2011. FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung … WebJan 8, 2024 · NIS793 is a monoclonal antibody blocking TGFβ1 and TGFβ2 and is being tested in combination with the anti-PD1 antibody PDR001 in a phase 1 clinical trial of patients with advanced malignancies ...
KR102512597B1 - 항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 …
WebPamrevlumab, our proprietary fully human antibody, targets connective tissue growth factor (CTGF), the central mediator of tissue remodeling and fibrosis. Pamrevlumab represents a potential treatment for a broad array of fibrotic and proliferative disorders that affect organ systems throughout the body. Pamrevlumab is in Phase 3 clinical studies for the … WebAug 6, 2024 · The efficacy of CTGF inhibition previously observed in a wide variety of animal models is now being evaluated in clinical trials. Therefore, CTGF appears to be a candidate therapeutic target for kidney disease. ... FG-3019, a human monoclonal antibody to CTGF, has been used in some animal models, including pulmonary fibrosis, peritoneal ... green card insurance italy
CTGF (D8Z8U) Rabbit mAb Cell Signaling Technology
WebClinical Trials Information. Find NCI-Supported Clinical Trials; What Are Clinical Trials? Paying for Clinical Trials; Patient Safety; Deciding to Take Part in a Trial; Questions to … WebAug 7, 2024 · Pamrevlumab, a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. WebMoreover, molecules aimed at blocking CTGF were identified to play an important role in the prevention of ocular fibrosis related to the TGFβ/Smad axis. The group of Wang et al. demonstrated that subconjunctival injection of a CTGF antibody was able to maintain larger bleb areas and lower intraocular pressures in a rabbit model of GFS . flowgenix spray